Abstracts tagged "Cardiovascular disease"

Abstract Number: 825 • 2015 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis and Estimation of Cardiovascular Risk in Systemic Sclerosis
Gulsen Ozen¹, Fatmanur Korkmaz², Murat Sunbul³, Rabia Deniz⁴, Kursat Tigen³, Pamir Atagunduz¹, Nevsun Inanc¹ and Haner Direskeneli¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Cardiology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Marmara University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: During the last decade, it has been shown that cardiovascular disease (CVD) in systemic sclerosis (SSc) is increased and accounts for ~30% of the…
Abstract Number: 1532 • 2015 ACR/ARHP Annual Meeting
Occurrence of Valvular Heart Disease in Rheumatoid Arthritis: A Population Based Study
Tamanna Khullar¹, John P. Bois¹, Cynthia S. Crowson², Megan L. Krause³ and Rekha Mankad¹, ¹Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of cardiovascular disease, particularly atherosclerosis and heart failure. However, little is known…
Abstract Number: 1687 • 2015 ACR/ARHP Annual Meeting
Increased Carotid Intima-Media Thickness in Psoriatic Arthritis Patients Compared with Systemic Lupus Erythematosus Patients and Healthy Controls
Handan Yarkan¹, Aslıgul Dunya², Pinar Cetin¹, Gercek Can¹, Nurullah Akkoc³ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey
Background/Purpose: The aim of this study was to investigate carotid intima-media thickness (IMT) in patients with psoriatic arthritis (PsA) and compare it with those in…
Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
JoAnne Foody¹, Robin Turpin², Beni Tidwell³ and Kathy Schulman⁴, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ³ORS, Shrewsbury, MA, ⁴Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
Abstract Number: 3237 • 2015 ACR/ARHP Annual Meeting
Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?
Elena Myasoedova¹, Cynthia S. Crowson², Eric L. Matteson³, John M. Davis III⁴, Terry M. Therneau⁵ and Sherine E. Gabriel⁶, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality as compared to the general population. Recent prospective studies with limited follow-up…
Abstract Number: 37 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors
Luis Rodriguez-Rodriguez^1,2, Pedro P Perrotti³, Adrìa Aterido³, Jesús Tornero⁴, Carlos Ferrandiz⁵, Juan D. Cañete⁶, Antonio Fernandez-Nebro⁷, Javier P Gisbert⁸, Eugeni Domènech^9,10, María López-Lasanta³, Sara Marsal³, Benjamín Fernández-Gutiérrez^1,11 and IMID Consortium, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ³Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁴Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ⁵Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁷Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ⁸Gastroenterology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁹Gastroenterology & Hepatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰CIBERehd, Madrid, Spain, ¹¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose : Our aim was 1) to analyze the association between demographic and traditional cardiovascular risk factors (CVRF) and cardiovascular disease (CVD) in subjects affected…
Abstract Number: 865 • 2015 ACR/ARHP Annual Meeting
Abdominal Visceral Adipose Tissue Measured By Dual Energy X-Ray Absorptiometry (DXA) As a Novel Surrogate Marker of Cardiovascular Risk in Primary Necrotizing Vasculitides
Bertrand Dunogué¹, Karine Briot², Sami Kolta², Alexis Regent¹, Pascal Cohen¹, Alice Berezne¹, Xavier Puéchal¹, Claire Le Jeunne¹, Luc Mouthon¹, Christian Roux², Loïc Guillevin¹ and Benjamin Terrier¹, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²Rheumatology B Department, Hôpital Cochin, Paris, France
Background/Purpose: Studies have shown a strong prevalence of cardiovascular events among patients with systemic necrotizing vasculitides (SNV). Recent studies indicate that visceral adipose tissue (VAT)…
Abstract Number: 1539 • 2015 ACR/ARHP Annual Meeting
Control of Modifiable Cardiovascular Risk Factors in Rheumatoid Arthritis Patients Compared to Traditional High-Risk Cardiovascular Disease Patients
Brian LaMoreaux¹, Alexa Meara² and Wael N. Jarjour³, ¹Rheumatology, The Ohio State University, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease affecting one percent of the population. The main cause of mortality among RA patients…
Abstract Number: 1696 • 2015 ACR/ARHP Annual Meeting
Score Classification Underestimates the Real Cardiovascular Risk in Psoriatic Arthritis Patients
Maria Paz Martínez-Vidal¹, Cristina Fernández-Carballido², Francisca Sivera³, Raquel Martín-Doménech¹, Nieves Martínez-Alberola¹ and Alejandro San Martin⁴, ¹Rheumatology, Hospital General Universitario Elda, ELDA, Spain, ²Rheumatology, Hospital General Universitario de Elda, Elda (Alicante), Spain, ³Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ⁴Rheumatology, Univesity General Hospital, ELDA, Spain
Background/Purpose: SCORE tables underestimate the Cardiovascular Risk (CVR) for patients with Rheumatoid Arthritis (RA) and EULAR recommends multiplying by 1.5 the CVR obtained from them…
Abstract Number: 2357 • 2015 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors for the Prevention of Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Markus Bredemeier¹, Matheus Augusto Eisenreich¹, Lediane Moreira Lopes¹, André Luis Bittencourt Morsch², Fernando da Silva Stein², Rui d'Avila² and Guilherme Gomes Dias Campos¹, ¹Rheumatology, Hospital Nossa Senhora da Conceição - Grupo Hospital Conceição, Porto Alegre, Brazil, ²Internal Medicine, Hospital Nossa Senhora da Conceição - Grupo Hospital Conceição, Porto Alegre, Brazil
Background/Purpose: There is evidence suggesting that high levels of uric acid represent an independent cardiovascular risk factor and that the use of xanthine oxidase inhibitors…
Abstract Number: 39 • 2015 ACR/ARHP Annual Meeting
Baseline Obesity and Subsequent Weight Loss Are Independently Associated with Cardiovascular Mortality in Established Rheumatoid Arthritis
Bryant R. England¹, Joshua F. Baker², Harlan Sayles³, Kaleb Michaud^4,5, Liron Caplan⁶, Lisa A. Davis⁶, Grant W. Cannon⁷, Brian Sauer⁸, E. Blair Solow⁹, Andreas Reimold¹⁰, Gail S. Kerr¹¹, Pascale Schwab¹² and Ted R. Mikuls¹³, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁸Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁰Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹¹VAMC, Georgetown University, Washington, DC, ¹²Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹³Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In the general population, higher body mass index (BMI) is associated with cardiovascular (CV) disease. However, an obesity paradox has been observed in rheumatoid…
Abstract Number: 954 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Osteoarthritis and Cardiovascular Disease: Results from a Population-Based Cohort
Lauren King¹, Tetyana Kendzerska^1,2,3 and Gillian Hawker^1,2,3, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
Background/Purpose: Symptomatic osteoarthritis (OA) and cardiovascular disease (CVD) commonly co-exist. Our aim was to determine the extent to which this relationship is explained by common…
Abstract Number: 1543 • 2015 ACR/ARHP Annual Meeting
Traditional Risk Score Underestimates the Cardiovascular Risk in Rheumatoid Arthritis Patients
Tomas Cazenave¹, Natalia Zamora¹, Gustavo Citera^1,2 and Marcos G. Rosemffet¹, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina
Background/Purpose: An increased incidence of cardiovascular (CV) mortality has been reported in patients with rheumatoid arthritis (RA). Adequate stratification of the CV risk is an…
Abstract Number: 1709 • 2015 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis in Patients with Psoriatic Arthritis and the Role of Vitamin D
Montserrat Robustillo-Villarino¹, Cristina Vergara-Dangond¹, Gloria Albert Espi¹, Marcos Cerqueira², Desamparados Ybañez García¹, Elia Valls¹, Elvira Vicens-Bernabeu¹, Juan José Alegre¹ and Àngels Martínez-Ferrer¹, ¹Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ²Hospital de Ponte de Lima, ULSAM, Department of Rheumatology,Hospital de Ponte de Lima, ULSAM, Ponte de Lima, Portugal
Background/Purpose: Psoriatic arthritis (PsA) is associated with increased cardiovascular risk (CV)[i]. Several studies associate low levels of 25-hydroxivitamin D (25OHD) with a greater prevalence of…
Abstract Number: 2413 • 2015 ACR/ARHP Annual Meeting
Contributors to Walking Disability in People with Osteoarthritis: Results from a Population-Based Cohort
Lauren King¹, Tetyana Kendzerska^1,2,3 and Gillian Hawker^1,2,3, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) is associated with functional limitations, including difficulty walking. However, comorbid disease is common in people with OA and may also be associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.